Cusatuzumab

Phase 2Monoclonal antibody

Cusatuzumab is one of 120 small molecule programs targeting Chronic Myelomonocytic Leukemia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

119

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Myelomonocytic LeukemiaActive, not recruiting

Myelodysplastic SyndromeActive, not recruiting

Acute Myeloid LeukemiaActive, not recruiting

Chronic Myelomonocytic LeukemiaPhase 2

Active, not recruiting

Myelodysplastic SyndromePhase 1

Active, not recruiting

Acute Myeloid LeukemiaPhase 2

Active, not recruiting

Competition

Competitive Landscape

804 competitors in Acute Myeloid Leukemia

#DrugCompanyPhaseTrials

Zarnestra

KKura Oncology, Inc.

Phase 3

9 2

Caspofungin Acetate

Merck & Co.

Phase 3

1 3

Oblimersen Sodium

NNational Cancer Institute (NCI)

Phase 3

3 4

Valspodar

EEastern Cooperative Oncology Group

Phase 3

3 5

GM-CSF

YY-mAbs Therapeutics

Phase 3

1 6

Homoharringtonine

Ascentage Pharma Group Inc.

Phase 3

1 7

Conventional Chemotherapy

SShanghai Jiao Tong University School of Medicine

Phase 3

1 8

Histamine Dihydrochloride

MMaxim Pharmaceuticals

Phase 3

1 9

Consolidation Chemotherapy

SShenzhen People's Hospital

Phase 3

1 10

Leukine

Sanofi

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Recruiting

Newly Diagnosed

NCT06384261

Clinical

Trials by Indication[1]

Acute Myeloid Leukemia2 trials

A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy

Active, not recruiting·OOncoVerity, Inc.·Phase 2·NCT04023526·103 enrolled

Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia

Active, not recruiting·OOncoVerity, Inc.·Phase 1·NCT04150887·61 enrolled

Newly Diagnosed1 trial

A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy

Recruiting·OOncoVerity, Inc.·Phase 2·NCT06384261·120 enrolled

Chronic Myelomonocytic Leukemia1 trial

A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hematopoietic Stem Cell Transplantation (HSCT)

Withdrawn· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT04264806

Myelodysplastic Syndrome1 trial

A Study of Cusatuzumab Plus Azacitidine in Japanese Participants With Newly Diagnosed Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Who Are Not Candidates for Intensive Treatment

Completed·OOncoVerity, Inc.·Phase 1·NCT04241549·6 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Cusatuzumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cusatuzumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cusatuzumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Johnson & Johnson company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 2[1]
Company: Johnson & Johnson

Cusatuzumab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Acute Myeloid Leukemia2 trials

Newly Diagnosed1 trial

Chronic Myelomonocytic Leukemia1 trial

Myelodysplastic Syndrome1 trial

References

Drug Info

Quick Facts

Related News